These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10438356)

  • 1. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
    Emery VC; Sabin C; Feinberg JE; Grywacz M; Knight S; Griffiths PD
    J Infect Dis; 1999 Sep; 180(3):695-701. PubMed ID: 10438356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus (CMV) polymerase chain reaction profiles in individuals with advanced human immunodeficiency virus infection: relationship to CMV disease.
    Nokta MA; Holland F; De Gruttola V; Emery VC; Jacobson MA; Griffiths P; Pollard RB; Feinberg JE;
    J Infect Dis; 2002 Jun; 185(12):1717-22. PubMed ID: 12085316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
    Griffiths PD; Feinberg JE; Fry J; Sabin C; Dix L; Gor D; Ansari A; Emery VC
    J Infect Dis; 1998 Jan; 177(1):57-64. PubMed ID: 9419170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
    Feinberg JE; Hurwitz S; Cooper D; Sattler FR; MacGregor RR; Powderly W; Holland GN; Griffiths PD; Pollard RB; Youle M; Gill MJ; Holland FJ; Power ME; Owens S; Coakley D; Fry J; Jacobson MA
    J Infect Dis; 1998 Jan; 177(1):48-56. PubMed ID: 9419169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
    N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).
    Erice A; Tierney C; Hirsch M; Caliendo AM; Weinberg A; Kendall MA; Polsky B;
    Clin Infect Dis; 2003 Aug; 37(4):567-78. PubMed ID: 12905142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation.
    Fiddian P; Sabin CA; Griffiths PD
    J Infect Dis; 2002 Oct; 186 Suppl 1():S110-5. PubMed ID: 12353195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic value of valacyclovir prophylaxis in transplantation.
    Squifflet JP; Legendre C
    J Infect Dis; 2002 Oct; 186 Suppl 1():S116-22. PubMed ID: 12353196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group.
    Salmon-Céron D; Fillet AM; Aboulker JP; Gérard L; Houhou N; Carrière I; Ostinelli J; Vildé JL; Brun-Vézinet F; Leport C
    Clin Infect Dis; 1999 Apr; 28(4):901-5. PubMed ID: 10825058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the late cytomegalovirus (CMV) pp150 transcript in leukocytes of AIDS patients is associated with a high viral DNA load in leukocytes and presence of CMV DNA in plasma.
    Boivin G; Handfield J; Toma E; Lalonde R; Bergeron MG
    J Infect Dis; 1999 May; 179(5):1101-7. PubMed ID: 10191210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy.
    O'Sullivan CE; Drew WL; McMullen DJ; Miner R; Lee JY; Kaslow RA; Lazar JG; Saag MS
    J Infect Dis; 1999 Sep; 180(3):847-9. PubMed ID: 10438377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The status of CMV viral load testing.
    Feinberg J
    AIDS Clin Care; 1996 Oct; 8(10):81. PubMed ID: 11363986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients.
    Grzywacz M; Deayton JR; Bowen EF; Wilson P; Emery VC; Johnson MA; Griffiths PD
    J Med Virol; 1999 Nov; 59(3):323-8. PubMed ID: 10502264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.
    Vusirikala M; Wolff SN; Stein RS; Brandt SJ; Morgan DS; Greer JP; Schuening FG; Dummer JS; Goodman SA
    Bone Marrow Transplant; 2001 Aug; 28(3):265-70. PubMed ID: 11535994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of polymerase chain reaction to provide prognostic information on human cytomegalovirus disease after liver transplantation.
    Lao WC; Lee D; Burroughs AK; Lanzani G; Rolles K; Emery VC; Griffiths PD
    J Med Virol; 1997 Mar; 51(3):152-8. PubMed ID: 9139077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
    Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
    J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
    J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
    Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
    Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients].
    Cartón JA; Maradona JA; de Oña M; Asensi V; Melón S; García-Alcalde ML; Rodríguez-Junquera M; Moreno-Torrico A; de Zárraga M
    Med Clin (Barc); 1999 Sep; 113(6):205-9. PubMed ID: 10472608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.